Ventola Cl

发表

Medical Applications for 3D Printing: Current and Projected Uses.

Ventola Cl, 2014 .

The role of pharmacogenomic biomarkers in predicting and improving drug response: part 2: challenges impeding clinical implementation.

Ventola Cl, 2013 .

Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?

Ventola Cl, 2011 .

Progress in Nanomedicine: Approved and Investigational Nanodrugs.

Ventola Cl, Ventola Cl, 2017 .

The antibiotic resistance crisis: part 2: management strategies and new agents.

Ventola Cl, Ventola Cl, 2015, P & T : a peer-reviewed journal for formulary management.

Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 1: The Widespread Use of CAM and the Need for Better-Informed Health Care Professionals to Provide Patient Counseling

Ventola Cl, 2010 .

An Interview Series with Members of the ASHP Expert Panel on Formulary Management: Part 2: J. Russell May, PharmD.

Ventola Cl, 2009 .

Biosimilars: Part 1: Proposed Regulatory Criteria for FDA Approval

Ventola Cl, 2013 .

Biosimilars: part 2: potential concerns and challenges for p&t committees.

Ventola Cl, 2013 .

Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions.

Ventola Cl, 2018 .

The nanomedicine revolution: part 1: emerging concepts.

Ventola Cl, Ventola Cl, 2012, P & T : a peer-reviewed journal for formulary management.

The Nanomedicine Revolution: Part 2: Current and Future Clinical Applications

Ventola Cl, 2012 .

Cancer Immunotherapy, Part 3: Challenges and Future Trends.

Ventola Cl, Ventola Cl, 2017 .